Addressing a Treatment GapRationale for Increasing the Starting Dose of Simvastatin in Hypercholesterolaemic Patients

被引：0
|
作者：
Jonathan Isaacsohn
Jonathan A. Tobert
Amy O. Johnson-Levonas
Pamela Landsman
机构：
[1] Metabolic and Atherosclerosis Research Center,Outcomes Research & Management
[2] Merck Research Laboratories,undefined
[3] Merck & Company Inc.,undefined
来源：
Clinical Drug Investigation | 2002年 / 22卷
关键词：
Coronary Heart Disease; Simvastatin; Coronary Heart Disease Risk; Multiple Risk Factor; Heart Protection Study;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：291 / 301
页数：10
相关论文
共 50 条
  • [1] Addressing a treatment gap - Rationale for increasing the starting dose of simvastatin in hypercholesterolaemic patients
    Isaacsohn, J
    Tobert, JA
    Johnson-Levonas, AO
    Landsman, P
    CLINICAL DRUG INVESTIGATION, 2002, 22 (05) : 291 - 301
  • [2] Rationale for increasing the starting dose of simvastatin
    Lucas, BD
    Elhabyan, AK
    Lucas, KH
    CLINICAL DRUG INVESTIGATION, 2002, 22 (09) : 639 - 639
  • [3] Rationale for Increasing the Starting Dose of Simvastatin
    B. Daniel Lucas
    Abdul-Karim Elhabyan
    Kristy H. Lucas
    Clinical Drug Investigation, 2002, 22 : 639 - 639
  • [4] Efficacy and Tolerability of Fluvastatin and Simvastatin in Hypercholesterolaemic Patients
    J. A. Tobert
    A. V. Katdare
    K.-L. Schulte
    S. Beil
    Clinical Drug Investigation, 1997, 13 (1) : 56 - 57
  • [5] Effects of simvastatin withdrawal on serum matrix metalloproteinases in hypercholesterolaemic patients
    Huang, CY
    Wu, TC
    Lin, WT
    Leu, HB
    Lin, CP
    Lin, SJ
    Chen, JW
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2006, 36 (02) : 76 - 84
  • [6] Efficacy and tolerability of fluvastatin and simvastatin in hypercholesterolaemic patients. Reply
    Schulte, KL
    Beil, S
    CLINICAL DRUG INVESTIGATION, 1997, 13 (01) : 56 - 57
  • [7] Sustained effects in hypercholesterolaemic patients on combined simvastatin/ezetimibe treatment: observational cohort study in clinical practice
    Hildemann, Steven K.
    Barho, Christian
    Karmann, Barbara
    Darius, Harald
    Bode, Christoph
    CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (10) : 2777 - 2784
  • [8] Simvastatin decreases monocyte chemoattractant protein-1 in hypercholesterolaemic patients
    Rallidis, L.
    Hamodraka, E.
    Moustogiannis, G.
    Salichou, C.
    Gika, H.
    Velissaridou, A.
    Kremastinos, D.
    ATHEROSCLEROSIS SUPPLEMENTS, 2006, 7 (03) : 574 - 574
  • [9] Pharmacogenetic study of cholesteryl ester transfer protein gene and simvastatin treatment in hypercholesterolaemic subjects
    Anagnostopoulou, Katherine
    Kolovou, Genovefa
    Kostakou, Peggy
    Mihas, Constantinos
    Mikhailidis, Dimitri
    Cokkinos, Dennis V.
    EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 (15) : 2459 - 2463
  • [10] Cellular cholesterol efflux to plasma from moderately hypercholesterolaemic type 1 diabetic patients is enhanced, and is unaffected by simvastatin treatment
    R. de Vries
    M. N. Kerstens
    W. J. Sluiter
    A. K. Groen
    A. van Tol
    R. P. F. Dullaart
    Diabetologia, 2005, 48 : 1105 - 1113
12345